FDA
-
-
-
-
-
-
-
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
-
-
-
-
-
-
-
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 TrialĀ in Patients with Idiopathic Pulmonary Fibrosis
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)
-
-
-
-
-
-
-
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Pliant Therapeutics (PLRX)
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Pliant Therapeutics (PLRX)
-
329,915 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

